{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 25,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Shows two parallel trial arms with timelines and patient counts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/19",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.65,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Trial design timeline showing two arms, randomization, and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51fc4f26-f14b-45a8-9fe9-8a382239948f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "image",
      "text": "Vaccitech logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87cec932-22e2-42c9-9b21-90da8e24937b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "image",
      "text": "Arbutus Biopharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9df10ec-b86b-41f1-b3d7-7540acabcbc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP-300 or placebo. At Week 48 all participants who are eligible to discontinue NA therapy will be followed for an additional 48 weeks. Expanded the clinical trial to include an additional arm with nivolumab (Opdivo), and dosed first patient in this arm in the first half of 2023. Full rights retained by the Companies of their respective product candidates and all costs split equally",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "420e4aeb-10df-4c7e-b07d-0c0539902d5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "POC Phase 2a clinical trial evaluating imdusiran in combination with Vaccitech's immunotherapeutic, VTP-300, with or without low dose nivolumab, and a NA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9310da36-7572-4501-81dd-048ebf83a1d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "AB-729-202: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f032d19-7662-4547-a729-fc9d5aee3b5a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "4f65ec39-c0f1-422d-9cfb-78546abfd9d3",
      "evidence": "The slide presents a clinical trial with Attention (primary objective: evaluate safety and reactogenicity), Interest (POC Phase 2a clinical trial evaluating imdusiran), Desire (imdusiran in combination with Vaccitech's immunotherapeutic, VTP-300), and Action (trial design timeline showing two arms, randomization, and follow-up periods).",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "dfe5841a-bc36-4ac9-afd7-59c7328f3dbb",
      "evidence": "The slide uses a timeline-based visual to represent clinical trial phases and patient cohorts.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}